Michael Ackermann is the founder of Tarsus Pharmaceuticals. Tarsus Pharmaceuticals has raised $260M in total funding. Latest round: IPO. Backed by Pharmakon.
Michael Ackermann is a drug researcher and developer at Tarsus Pharmaceuticals, recognized as an Elite 2021 Drug Researcher. He was involved in the development of TP-03, a drug which achieved collarette cure and mite eradication in Phase 2 trials and received FDA approval in July 2023.
Full founder directory · Investor directory · Company funding database · Fundraising library
The Startup Fundraising Platform
Raise funds for your startup
Find the right investors and get real replies — instantly, powered by AI.
Takes 30 seconds · No credit card · Cancel anytime
Slide-by-slide guide